Cell-permeable peptide inhibitors of the JNK signal transduction pathway

(19)

(11)

EP 1 905 830 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	11.04.2012 Bulletin 2012/15

(45)	Mention of the grant of the patent:
	07.03.2012 Bulletin 2012/10

(21)	Application number: 07021046.3

(22)	Date of filing: 12.10.2000

(51)

International Patent Classification (IPC):

C12N 15/12^(2006.01)
C07K 14/47^(2006.01)

C12N 15/62^(2006.01)
A61K 38/17^(2006.01)

(54)	Cell-permeable peptide inhibitors of the JNK signal transduction pathway Zelldurchlässige Peptidhemmer des JNK-Signaltransduktionsweges Inhibiteurs peptidiques à perméabilité cellulaire du processus de transduction du signal de JNK

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30)

Priority:

12.10.1999 US 158774 P
14.02.2000 US 503954

(43)	Date of publication of application:
	02.04.2008 Bulletin 2008/14

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	00969730.1 / 1303600

(73)	Proprietor: Xigen S.A.
	1066 Epalinges (CH)

(72)	Inventor:
	Bonny, Christophe 1006 Lausanne (CH)

(74)	Representative: Graf von Stosch, Andreas et al
	Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstrasse 22 80538 München 80538 München (DE)

(56)

References cited: :

EP-A- 0 897 002
WO-A-98/44106

WO-A-94/04686
WO-A-98/49188

DICKENS M ET AL.: "A cytoplasmic inhibitor of the JNK signal transduction pathway" SCIENCE, vol. 277, no. 5326, 1 August 1997 (1997-08-01), pages 693-696, XP002172257
YASUDA J ET AL.: "The JIP group of mitogen-activated protein kinase scaffold proteins" MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 10, October 1999 (1999-10), pages 7245-7254, XP002172259
BONNY C ET AL.: "IB1, a JIP-1-related nucelar protein present in insulin-secreting cells" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 4, 23 January 1998 (1998-01-23), pages 1843-1846, XP002172258
VIVÈS E ET AL.: "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 25, 20 June 1997 (1997-06-20), pages 16010-16017, XP002172260
BONNY C ET AL.: "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death." DIABETES, vol. 50, no. 1, January 2001 (2001-01), pages 77-82, XP002172261

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).